Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials - PubMed
7 hours ago
- #PD-1 inhibitors
- #rectal cancer
- #meta-analysis
- Meta-analysis evaluates neoadjuvant chemoradiotherapy (nCRT) with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer.
- Addition of PD-1 inhibitors to nCRT significantly increases pathological complete response (pCR), especially with short-course radiotherapy.
- No significant differences observed in R0 resection, sphincter preservation, or high-grade neoadjuvant toxicity between groups.
- Six randomized trials included, evaluating PD-1 inhibitors like pembrolizumab, sintilimab, tislelizumab, and camrelizumab.
- Findings support progression to phase III trials for further validation of PD-1 inhibitors in this setting.